Medical Devices Startups

KelaHealth develops data-driven solutions that apply insights from millions of patient records to personalize and improve medical decision-making. The platform serves healthcare providers seeking to deliver safer, evidence-based care tailored to individual patients.

5 investors

Kitea Health is a medical device company spun out of the Auckland University Bioengineering Institute, developing the Kitea System, a microscale wireless sensor technology with applications in hydrocephalus and cerebrospinal fluid monitoring. Based in New Zealand, it aims to translate bioengineering research into clinical products for patients globally.

5 investors

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

5 investors

LambdaVision develops a protein-based artificial retina designed to restore vision for patients blinded by advanced retinal degenerative diseases such as retinitis pigmentosa and age-related macular degeneration. The implant uses proteins similar to the visual pigment rhodopsin to mimic the light-absorbing function of damaged photoreceptor cells, and its manufacturing leverages space-based production.

5 investors

LetsGetChecked provides at-home healthcare including lab testing, virtual consultations, and prescription fulfillment, backed by its own manufacturing, logistics, and lab analysis infrastructure plus proprietary clinical and analytics software. It serves individual patients and over 5,000 corporate and healthcare partners globally.

5 investors

MagentaMed develops the Elevate percutaneous Left Ventricular Assist Device (pLVAD), a low-profile, high-flow arterial pump for temporary mechanical circulatory support. It is intended for patients undergoing high-risk coronary interventions and those admitted with cardiogenic shock.

5 investors

Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network. The site serves as a landing page directing visitors to the two separate pharmaceutical companies.

5 investors

Materna Medical develops medical devices for women's pelvic health, including the FDA-cleared Milli vaginal dilator for treating vaginismus and painful intercourse, and the investigational Ellora System for labor support. The company serves women experiencing pelvic health challenges from conditions including menopause, postpartum recovery, cancer side effects, and sexual trauma.

5 investors

MediWound is a biotechnology company developing enzymatic treatments that selectively remove eschar tissue while preserving healthy tissue for burns and chronic wounds. Its products include NexoBrid, an approved therapy for severe thermal burns, and EscharEx, a candidate for debridement of chronic and hard-to-heal wounds, serving hospitalized and wound care patients worldwide.

5 investors

Mission Bio develops single-cell biology tools and platforms for researchers and clinicians to enable precision medicine discovery and cancer treatment. The company serves the biomedical research and clinical diagnostics market.

5 investors

Neusignal Therapeutics develops novel drugs for central nervous system disorders, including dementia and psychiatric conditions, with research focused on calcium signaling in neurons and target discovery for brain diseases. The company serves the pharmaceutical/biotech market and is based in Tokyo, Japan.

5 investors

Neuspera Medical develops an integrated sacral neuromodulation (iSNM) system that implants a smart neurostimulator near the sacral nerve to treat urinary urge incontinence, a symptom of overactive bladder. Its device is powered by a discreet, wirelessly charged external battery worn daily, targeting patients—particularly women in the U.S.—affected by these conditions.

5 investors

Nimble Sciences develops the SIMBA GI Platform, a swallowable capsule system that autonomously collects, seals, and preserves fluid biopsies from the small intestine to generate multi-omic datasets of the GI tract. The platform is used to characterize the gut microbiome, correlate multi-omic profiles with disease states, and support therapeutic and microbiome-related research in gastrointestinal care.

5 investors

Noah Medical develops the Galaxy System, a robotic bronchoscopy platform that integrates advanced imaging, precision targeting, and adaptive workflow for real-time lesion localization and lung diagnostics. The system is used by interventional pulmonologists and hospitals to improve diagnostic yield and accuracy.

5 investors

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.

5 investors

Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes. The company targets patients living with chronic conditions such as restless legs syndrome, offering prescription-grade therapy through medical devices.

5 investors

Nomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies. It targets researchers doing proteomics work, aiming for high-throughput, low-cost profiling in the biotech and life sciences market.

5 investors

Noninvasix develops a patented optoacoustic platform that non-invasively and continuously measures central venous oxygen saturation to help ICU clinicians diagnose and monitor tissue hypoxia in sepsis and septic shock patients in real time. The technology is aimed at critical care settings, with planned applications in fetal monitoring, neonatal care, traumatic brain injury, and blood loss.

5 investors

Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation. The company targets patients with chronic inflammatory and autoimmune conditions.

5 investors

On Target Laboratories is a company of scientists and researchers focused on cancer surgery, developing products to support surgical oncology. It operates in the biotech and medtech space.

5 investors

Oncoustics develops ultrasound-based artificial intelligence and machine learning solutions for cancer detection and liver disease characterization, serving clinical researchers and healthcare providers. The company operates research collaborations with Stanford University, University of Toronto, and international health institutes across Toronto, Cairo, and Palo Alto.

5 investors

OncoveryCare develops survivorship care solutions for cancer survivors, addressing the medical and quality-of-life needs of people living after cancer treatment.

5 investors

ONI develops the Nanoimager, an automated super-resolution imaging system. The company serves researchers and laboratories in life sciences and microscopy applications.

5 investors

Overt Bio develops cell therapies that link genes to immune functions using genome-scale discovery platforms. The company builds programmable immunotherapies targeting cancer patients.

5 investors